AstraZeneca hit the pandemic: Pharmaceutical manufacturer’s profit doubles in 2020 – News by sources

Pharmaceutical manufacturer AstraZeneca reported a profit of $ 3.2 billion for 2020 on Thursday, more than double compared to 2019, in a year marked by a coronavirus pandemic against which the British group has developed a vaccine with Oxford University , transmits AFP, according to AGERPRES.

AstraZeneca Group sales also rose 9 percent to $ 26.6 billion, thanks to new drugs and strong demand for anti-virus products such as asthma. This increase offset the decline in revenue generated by other products, in which the distribution to patients was slowed by the pandemic, especially in oncology, due to the postponement of treatments to give priority to those against coronavirus.

“The success of developing drugs, the acceleration of our company’s performance and the progress of the vaccine against Covid-19 show what we can achieve, while the $ 39 billion Alexion acquisition project aims to accelerate our commercial and scientific development,” said the CEO. Pascal Soriot.

Deputy Prime Minister Kelemen Hunor responds to student criticism: ‘I didn’t break a promise’

For 2021, AstraZeneca expects revenue growth of a few percent and a higher profit than in 2020, but points out that these forecasts do not take into account sales of vaccines against the virus, for which it will start publishing results from the next quarter.

The pharmaceutical group recalls that in December it received emergency approval to start distributing its vaccine in the UK, followed by India, Argentina, Mexico, Morocco and the European Medicines Agency. AstraZeneca also points out that it has started the third phase of testing for an antibody-based drug against Covid-19.

AstraZeneca is committed to providing 170 million doses of vaccine in 190 countries.

With an average efficiency currently assessed at 70%, the AstraZeneca / Oxford vaccine is below the performance assigned to Pfizer / BioNTech or Moderna, with an efficacy of over 90%. However, this vaccine uses a more traditional technology, which makes it less expensive, easier to store and therefore more suitable for mass vaccination campaigns.

In Romania, the second tranche of the AstraZeneca vaccine, 92,400 doses, arrives in Romania by land on Thursday, the National Committee for the Coordination of Vaccination Activities (CNCAV) informed against COVID-19.


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.